Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...
“The First Street water main project was identified as a pretty big risk within our asset management program. It’s an older, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results